Jefferies initiated coverage of Moderna (MRNA) with a Hold rating and $30 price target For 2026, the company’s Covid and RSV sales should grow ex-US with operating expense also falling about 8%, but while this is directionally helpful, Moderna will need more to meet guide, the analyst tells investors in a research note. Moderna’s pipeline also needs to progress to drive non-Covid revenue to $3B, the firm added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderately bullish activity in Moderna with shares up 0.53%
- FDA probe into COVID vaccines includes adults, Bloomberg reports
- FDA to investigate COVID vaccine safety across age groups
- Moderna’s Growth Prospects: Balancing Revenue Potential and Legal Challenges
- Mixed options sentiment in Moderna with shareslittle changed